Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

45

Revenue 2017

Zytiga

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Zytiga was produced by Janssen.

Generic threat looms to J&J’s blockbuster Zytiga in US

Generic threat looms to J&J’s blockbuster Zytiga in US

Zytiga will enter the market and will result in a significant decline in sales.”. ... J&J isn’t the only company that would be affected by an early generic Zytiga launch.

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use

Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use The expanded licence will help it compete with J&J’S rival treatment Zytiga, which has also been broadening into patients with earlier stage disease.

Daily Brief:  NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal

Daily Brief:  NICE says no to Zytiga, Genentech and UK biotech sign microbiome deal UK Market Access. NICE says no to Zytiga. NICE has rejected Janssen’s Zytiga plus androgen deprivation therapy (ADT) for men with untreated high-risk hormone-sensitive metastatic prostate cancer (mHSPC). ... Around half of patients unable to tolerate

EMA starts review of Xtandi in non-metastatic prostate cancer

EMA starts review of Xtandi in non-metastatic prostate cancer At the moment Xtandi - like longstanding rival Zytiga (abiraterone acetate) from Johnson &Johnson - is only prescribed for men with advanced CRPC that has spread and no longer responds to hormone therapy.

PROSPER data reveal big Xtandi benefit in early-stage prostate cancer

PROSPER data reveal big Xtandi benefit in early-stage prostate cancer At the moment Xtandi, in common with a rival therapy from Johnson &Johnson called Zytiga (abiraterone acetate), is only prescribed for men with advanced CRPC that has spread and no longer ... The market category will see some significant disruption later

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics